Hannah Palac

ORCID: 0000-0003-1314-3329 · 5 papers in corpus · active 2018-2019

Study types

  • article 5

Condition tags

  • endometriosis 4
  • dyspareunia 1
article 2019
Elagolix reduced dyspareunia and improved health-related quality of life in premenopausal women with endometriosis-associated pain
·doi:10.1177/2284026519872401

Objectives: The objective was to evaluate the effects of elagolix on dyspareunia in women with endometriosis-associated pain. Methods: Data were pooled from two similar, randomized, double-blind, placebo-controlled, 6-month phase 3 studies …

article 2019
Impact of Elagolix on Quality of Life Among Endometriosis Patients: A Pooled Analysis of 2 Phase III Clinical Trials [13J]
·doi:10.1097/01.aog.0000558829.95268.69

INTRODUCTION: Endometriosis-associated symptoms are associated with reduction in health-related quality of life (HRQL). This analysis evaluated the impact of Elagolix, an oral gonadotrophin releasing-hormone antagonist, on the HRQL of women…

article 2019
Impact of Elagolix on Workplace and Household Productivity Among Women with Moderate to Severe Pain Associated with Endometriosis: A Pooled Analysis of Two Phase III Trials
The patient ·doi:10.1007/s40271-019-00394-7

BACKGROUND: Endometriosis profoundly impairs women's workplace and household productivity. OBJECTIVE: The aim of this study was to evaluate the impact of elagolix on endometriosis-related workplace and household productivity losses. METHODS…

article 2019
PIH62 ELAGOLIX REDUCES WORK PRODUCTIVITY LOSSES AMONG WOMEN WITH MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS
·doi:10.1016/j.jval.2019.04.862
article 2018
Bone turnover changes in women treated with elagolix or placebo during the elaris EM-I and EM-II trials who did not continue in the extension studies
·doi:10.1016/j.fertnstert.2018.07.053